On August 19, the U.S. Food and Drug Administration (FDA) approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, which affects about 6,000 people in the United States. Read more.
Most Recent Content
For Nurse Practitioners
Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could
Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...
